Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Health related quality of life findings from COMBI-AD

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 541

Prof Dirk Schadendorf - Hospitals Essen-Mitte, Essen, Germany

Dr Schadendorf speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago about patient perspectives and QOL feedback following adjuvant treatment with dabrafenib and trametinib to treat resected stage III BRAF melanoma.

Dr Schadendorf notes that during treatment in the COMBI-AD trial, which ecancer reported on here, up to a quarter of patients discontinued treatment due to toxicity.

Ultimately those that remained in the trial saw their quality of life improve, and he considers how better communication of expectations in treatment tolerability may boost trial retention, and ultimately survival.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation